Literature DB >> 15011812

The history of gold therapy for tuberculosis.

Thomas G Benedek1.   

Abstract

This is a historical study of the popularization of a medical therapy contrary to pertinent experimental findings. Presumably this circumstance reflects the desperation about tuberculosis: highly prevalent, highly fatal, and lacking any etiologically directed therapy. Gold compounds were introduced, based initially on the reputation of Robert Koch, who had found gold cyanide effective against M. tuberculosis in cultures, but not in experimentally infected animals. Treatment of pulmonary tuberculosis with these compounds was popularized, particularly by Danish physicians, in the mid-1920s, despite consistently negative experimental results, based on Paul Ehrlich's theories of antimicrobial drug effects. Difficulties in the design of interpretable clinical studies were soon recognized but also generally ignored, thus permitting data to be interpreted as favorable to antituberculous gold therapy. Eventually toxicity was considered to outweigh the alleged therapeutic benefit of all gold compounds. This resulted in their discard shortly before the introduction of streptomycin therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15011812     DOI: 10.1093/jhmas/jrg042

Source DB:  PubMed          Journal:  J Hist Med Allied Sci        ISSN: 0022-5045            Impact factor:   2.088


  14 in total

1.  Human Serum Albumin-Delivered [Au(PEt3)]+ Is a Potent Inhibitor of T Cell Proliferation.

Authors:  Tyler C Dean; Mu Yang; Mingyong Liu; Jason M Grayson; Anthony W DeMartino; Cynthia S Day; Jingyun Lee; Cristina M Furdui; Ulrich Bierbach
Journal:  ACS Med Chem Lett       Date:  2017-04-25       Impact factor: 4.345

2.  Unexpected intracellular biodegradation and recrystallization of gold nanoparticles.

Authors:  Alice Balfourier; Nathalie Luciani; Guillaume Wang; Gerald Lelong; Ovidiu Ersen; Abdelali Khelfa; Damien Alloyeau; Florence Gazeau; Florent Carn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-18       Impact factor: 11.205

Review 3.  Gold-based therapy: From past to present.

Authors:  Alice Balfourier; Jelena Kolosnjaj-Tabi; Nathalie Luciani; Florent Carn; Florence Gazeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

Review 4.  Aurothiomalate-Based Drugs as Potentially Novel Agents Against Leishmania major: A Mini Review.

Authors:  Ali Davoodi; Shahram Eslami; Mahdi Fakhar; Mohammad Aazadbakht; Mahbobeh Montazeri; Elnaz Khoshvishkaie; Masoud Keighobadi
Journal:  Acta Parasitol       Date:  2022-04-05       Impact factor: 1.440

5.  N-heterocyclic carbene gold(I) and silver(I) complexes bearing functional groups for bio-conjugation.

Authors:  Mary E Garner; Weijia Niu; Xigao Chen; Ion Ghiviriga; Khalil A Abboud; Weihong Tan; Adam S Veige
Journal:  Dalton Trans       Date:  2015-01-28       Impact factor: 4.390

6.  Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Rashmi Gupta; Carolina Rodrigues Felix; Matthew P Akerman; Kate J Akerman; Cathryn A Slabber; Wenjie Wang; Jessie Adams; Lindsey N Shaw; Yuk-Ching Tse-Dinh; Orde Q Munro; Kyle H Rohde
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Gold(I) analogues of a platinum-acridine antitumor agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis.

Authors:  Lauren C Eiter; Nathan W Hall; Cynthia S Day; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

Review 8.  Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds.

Authors:  Ningning Liu; Hongbiao Huang; Q Ping Dou; Jinbao Liu
Journal:  Oncoscience       Date:  2015-05-31

Review 9.  Synthesis and structural activity relationship study of antitubercular carboxamides.

Authors:  D I Ugwu; B E Ezema; F U Eze; D I Ugwuja
Journal:  Int J Med Chem       Date:  2014-12-30

10.  The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosis compared to Bacillus Calmette-Guérin but with similar lung inflammatory effects.

Authors:  Fábio Muniz de Oliveira; Monalisa Martins Trentini; Ana Paula Junqueira-Kipnis; André Kipnis
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-04       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.